Tagged with GEN

India Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous nation are responding to the drastic need for quality, affordable generic medicines across the world. “When it comes to manufacturing…

Poland Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the need for data transparency in constructing correct strategies for clients. She also highlights the role KPMG is playing in bringing…

Bulgaria Kalin Tochev, country manager of IQVIA Bulgaria, discusses the main trends taking place in the Bulgarian pharmaceutical sector and highlights the end-to-end approach that IQVIA offers to its clients to help them successfully navigate a dynamic environment. Mr. Tochev, you have a quite unusual profile coming from different industries such…

Japan Yuzo Toda, chairman of the Forum for Innovative Regenerative Medicine (FIRM) in Japan, discusses how the organization acts as a translational bridge between academia and industry, how the paradigm of regenerative medicine differs from that of traditional pharmaceuticals, and why Japan has taken the lead in this exciting new field.…

Canada Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative, affordable generics to patients. He furthermore expresses his hopes for collaboration between generic players in the Canadian pharmaceutical industry in…

Brazil Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land of many opportunities. He is looking forward to capitalize the fast growth rate of generic products in Brazil, revive the…

Canada Louis Pilon, president and CEO, highlights JAMP Pharma’s unique positioning as a Canadian generics company with one of the largest salesforce covering the whole Canadian market as well as the fourth-largest product portfolio, their focus on niche and complex products, their agility in seizing new opportunities, and his mission to…

Brazil Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for Brazilians, and the company’s current research on immunostimulants. Before presenting the company, could you tell our readers what motivated you…

Poland Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to its Rx generics. Furthermore, he highlights the potential of Poland to be a key player within the company’s international success…

Canada Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio in the four business segments of generics, biosimilars, consumer (OTC) and specialty products. He talks about the quality of the…

India India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence of gender disparity in India, where only two percent of women attain leadership positions; several inspirational women are blazing trails…

Canada Stefan Larson, CEO of Northern Biologics, explains the major milestones for Northern Biologics over the past three years, his personal motivation for starting a biotech company, their collaboration with Celgene, and his thoughts on the strengths and areas for growth within the Canadian biotech industry. Stefan, three years into the…